Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-06-01 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于召开2017年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice for convening the 2017 third extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It details the meeting date, voting methods, agenda items including share repurchase proposals, and instructions for shareholders. It does not contain actual financial statements or results but is an announcement about the meeting and its procedures. The document length is about 3,000 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2017-06-01 Chinese
独立董事关于公司共同发起设立昆明高新诺泰大健康产业投资合伙企业（有限合伙）所涉关联交易的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding a related-party transaction involving the establishment of an investment partnership. It references regulatory guidelines for independent directors and discusses the fairness and impact of the transaction on shareholders. The document is short (645 characters) and does not contain financial statements or detailed financial data. It is not a full report but an opinion related to a corporate governance matter and a related-party transaction. This fits best under Regulatory Filings (RNS) as it is a regulatory disclosure related to governance and related-party transactions but not a full governance report or management report.
2017-06-01 Chinese
八届三十二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed by the board of directors of Kunming Pharmaceutical Group Co., Ltd. It includes voting results on various proposals such as a restricted stock incentive plan, share repurchase plan, establishment of an investment partnership, and amendments to agreements. The document is titled as a board meeting resolution announcement and contains no financial statements or detailed financial data. It is not a full annual or interim report, nor an earnings release. It is not a proxy solicitation or shareholder meeting notice but a board/management information disclosure about board decisions. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 4101 characters, which is sufficient for a detailed board resolution announcement.
2017-06-01 Chinese
关于招商证券为“15昆药债”出具2016年度受托管理事务报告的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (453 characters) regarding the issuance of a trustee management report for a company bond for the year 2016. It states that the trustee management report was issued by the trustee (招商证券) and that the detailed report can be found on the Shanghai Stock Exchange website. The document does not contain the report itself but is a notice about the report's issuance and availability. According to the 'Menu vs Meal' rule, such short announcements that notify about a report being issued and available elsewhere should be classified as Report Publication Announcement (RPA).
2017-05-26 Chinese
2015年公司债券受托管理事务报告（2016年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "2015年公司债券受托管理事务报告 (2016年度)" which translates to "2015 Company Bond Trustee Management Affairs Report (2016 Annual)". It is issued by Kunming Pharmaceutical Corp and includes detailed financial data, operating performance, bond issuance details, bondholder meeting information, bond interest payment status, credit rating updates, and other related information for the year 2016. The document is comprehensive and contains actual financial statements and analysis related to the bond issuance and the company's financial condition for the year 2016. It is not an announcement of a report but the report itself. The content focuses on bond trustee management affairs, which is a type of audit or regulatory report related to bond issuance and management, rather than a full annual report or earnings release. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2016
2017-05-26 Chinese
关于“15昆药债”2017年跟踪评级结果公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the 2017 follow-up credit rating results for the company's 2015 bond issuance. It references regulatory rules and the rating agency's report but does not contain the full rating report or detailed financial data. The document length is only 636 characters, indicating it is a brief announcement rather than a full report. It states that the detailed rating report can be found on the exchange website, which aligns with an announcement of a report rather than the report itself. Therefore, this fits best as a Regulatory Filing (RNS) since it is a regulatory announcement about credit rating results without substantive financial statements or detailed report content.
2017-05-24 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.